Arrowhead’s plozasiran holds potential to treat dyslipidemia, says analyst

16 April 2024

US biotech Arrowhead Pharmaceuticals (Nasdaq: ARWR) recently unveiled final data from its Phase II SHASTA-2 clinical trial for plozasiran, previously recognized as ARO-APOC3.

The data indicates a substantial reduction in apolipoprotein C-III (APOC3) and triglycerides by as much as 86% and 90%, respectively. Should it secure approval, plozasiran holds potential to effectively address critical unmet needs in dyslipidemia management, says pharma analytics company GlobalData.

GlobalData’s report, “ Dyslipidemia: Seven-Market Drug Forecast and Market Analysis,” reveals that plozasiran, an antisense RNA-interference oligonucleotide, is expected to reach $707 million in sales in 2032.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK